2020 American Transplant Congress
Safety and Efficacy of Prophylactic Valganciclovir Dosing after Solid Organ Transplant
Loyola University Medical Center, Maywood, IL
*Purpose: At centers where antiviral prophylaxis is used after solid organ transplant, valganciclovir is administered for the prevention of cytomegalovirus (CMV). At Loyola University Medical…2020 American Transplant Congress
Impact and Outcomes of Primary Cytomegalovirus Infection in Seronegative Abdominal Solid Organ Transplant Recipients of Cytomegalovirus Unexposed Donors (D-/R-)
1UWHC, Madison, WI, 2UWMF, Madison, WI
*Purpose: Primary cytomegalovirus infection (CMV) in high risk (D+/R-) abdominal solid organ transplant recipients (aSOTRs) is well described, however there is a paucity of literature…2020 American Transplant Congress
Crispr-Based Diagnostics for Rejection and Opportunistic Infection Detection in Kidney Transplantation
*Purpose: There is an unmet need in transplantation to identify allograft injury non-invasively. More than 50% of patients with kidney transplants lose their grafts within…2020 American Transplant Congress
Efficacy and Safety According to Dose of Valganciclovir for Cytomegalovirus Prophylaxis in Transplantation Network Meta Analysis
Inha University, Incheon, Korea, Republic of
*Purpose: Valgancivlovir is importantly used to prevent post-transplant CMV infection among kidney transplantation patients. However, the dose of such drug being used still remains controversial…2020 American Transplant Congress
Multicenter Evaluation of Cytomegalovirus Infection Following Intestinal and Multivisceral Transplantation
1Duke University Hospital, Chapel Hill, NC, 2Henry Ford Hospital, Detroit, MI
*Purpose: Evaluate factors related to incidence and outcomes of cytomegalovirus (CMV) infection after isolated intestinal transplantation (IT) and multivisceral transplantation (MVT).*Methods: Retrospective evaluation of 32…2020 American Transplant Congress
Conversion to Sirolimus to Prevent Recurrent Cytomegalovirus Infection/Disease: A Prospective and Randomized Trial
Hospital do Rim - UNIFESP, São Paulo, Brazil
*Purpose: Recurrent cytomegalovirus (CMV) infection occurs in 30-35% of kidney transplant recipients after completion of treatment and/or preemptive therapy. There is no consensus on the…2020 American Transplant Congress
Influence of HLA Compatibility on Cytomegalovirus Infection Post-Kidney Transplantation
*Purpose: Cytomegalovirus (CMV) infection after kidney transplantation is associated with a high morbidity and higher risk of graft loss. A latent Human CMV infection can…2020 American Transplant Congress
Identification of Cell Types That Harbor Cytomegalovirus DNA in Acutely and Latently Infected Mice Spleen
*Purpose: Cytomegalovirus (CMV) is a ubiquitous β‐herpesvirus that infects majority of humans. Primary CMV infection may be asymptomatic or manifests as a self‐limited febrile illness…2019 American Transplant Congress
Impact of Cytomegalovirus on the Immune System of Healthy Humans
Emory Transplant Center, Emory University, Atlanta, GA
*Purpose: CMV is a frequent pathogen after transplantation. 2/3 of recipients harbor latent CMV and are at moderate risk. CMV- recipients divide into high or…2019 American Transplant Congress
Letermovir for CMV Treatment in Solid Organ Transplant
The Ohio State University Wexner Medical Center, Columbus, OH
*Purpose: Letermovir (LET), a novel anti-CMV agent, was recently approved for CMV prophylaxis in stem cell transplant recipients and is currently under investigation as a…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 33
- Next Page »